Shanghai Shyndec Pharmaceutical's subsidiary has obtained the drug registration certificate for sustained-release quetiapine fumarate tablets.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd. (referred to as CNPG Industrial), recently received the approved and issued Drug Registration Certificate for Quetiapine Sustained-Release Tablets by the National Medical Products Administration. Quetiapine Sustained-Release Tablets is an atypical antipsychotic medication that regulates brain nerve activity. It is primarily used to control schizophrenia and bipolar disorder, stabilizing mood, reducing hallucinations, and improving cognitive function. It helps patients recover normal cognitive and social functions.